Chronic Pancreatitis, Pancreatic Insufficiency, Pancreatic Surgey, SIBO
Conditions
Keywords
Pancreatic exocrine insufficiency, Chronic pancreatitis, enzyme replacement therapy, Small intestinal bacterial overgrowth
Brief summary
Pancreatic exocrine insufficiency (PEI) results from reduced pancreatic enzyme secretion, leading to malabsorption, malnutrition, and impaired quality of life. Although pancreatic enzyme replacement therapy (PERT) is the standard treatment, some patients remain symptomatic despite apparently adequate therapy. Possible causes include suboptimal dosing or concomitant conditions such as small intestinal bacterial overgrowth (SIBO). This study aims to determine the prevalence of SIBO in symptomatic PEI patients despite adequate PERT and to identify treatable causes of persistent symptoms using non-invasive diagnostic tests, with the goal of improving nutritional status and quality of life.
Detailed description
Pancreatic exocrine insufficiency (PEI) is defined as a reduction in pancreatic exocrine secretion below the level required for normal digestion of nutrients, leading to malabsorption, malnutrition, reduced quality of life, and increased morbidity. Chronic pancreatitis represents the most common cause of PEI, although the condition may also develop after pancreaticoduodenectomy. Pancreatic enzyme replacement therapy (PERT) with pancrelipase is the standard treatment and is effective in most patients. However, a proportion of individuals continue to experience gastrointestinal symptoms and weight loss despite apparently adequate therapy, possibly due to suboptimal dosing or concomitant conditions such as small intestinal bacterial overgrowth (SIBO). The mixed triglyceride breath test may help evaluate the adequacy of enzyme replacement therapy, while non-invasive breath tests using glucose or lactulose represent practical diagnostic alternatives for SIBO. This study aims to determine the prevalence of SIBO in patients with PEI who remain symptomatic despite adequate PERT and to identify treatable causes of persistent gastrointestinal symptoms and malnutrition through non-invasive diagnostic tests, with the ultimate goal of improving patients' nutritional status and quality of life.
Interventions
None listed
Sponsors
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years * Ability and willingness to participate in the study and to comply with study procedures * Diagnosis of chronic pancreatitis with pancreatic exocrine insufficiency (defined as fecal elastase \< 200 µg/g of stool) * Ongoing pancreatic enzyme replacement therapy (PERT) with persistent gastrointestinal symptoms (including abdominal pain, dyspepsia, bloating, excessive flatulence, diarrhea, or steatorrhea) or unintentional weight loss ≥ 10% within the previous 6 months despite adequate PERT dosing (≥ 40,000 IU per main meal and half dose for snacks) * Patients with ampullary or pancreatic tumors who underwent partial pancreatectomy and subsequently developed pancreatic exocrine insufficiency with persistent gastrointestinal symptoms * Indication to undergo glucose, lactulose, and mixed triglyceride breath tests as part of routine clinical practice * Signed written informed consent
Exclusion criteria
* Age \< 18 years or \> 75 years * Pancreatic adenocarcinoma or bile duct tumors under active or previous adjuvant therapy * Moderate to severe liver disease * Severe chronic kidney disease (eGFR \< 30 mL/min/1.73 m²) * History of major gastrointestinal surgery, including total pancreatectomy * Presence of other active organic gastrointestinal diseases * Diabetic gastroparesis * Known celiac disease * Obstructive jaundice * Liver cirrhosis Child-Pugh class C * Recent or ongoing infections * Severe chronic obstructive pulmonary disease (COPD) * Symptomatic thyroid disorders * Use of antibiotics, laxatives, probiotics, or prokinetic agents within 4 weeks prior to breath testing * Inability or refusal to undergo study procedures * Inability or refusal to provide informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prevalence of Small Intestinal Bacterial Overgrowth (SIBO) | Baseline | Assessment of the prevalence of SIBO among two patient groups: 1. individuals with chronic pancreatitis and pancreatic exocrine insufficiency (PEI), and 2. patients who underwent partial pancreatectomy and subsequently developed PEI. SIBO will be diagnosed using glucose and lactulose hydrogen breath tests according to international diagnostic criteria. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Improvement of Gastrointestinal Symptoms After Antibiotic Treatment | Up to 3 months after treatment | Evaluation of reduction or resolution of gastrointestinal symptoms (including abdominal bloating, abdominal pain, diarrhea, excessive flatulence) following antibiotic therapy in participants diagnosed with SIBO. |
| Identification of Alternative Causes of Persistent Symptoms | Baseline to 3 months | Investigation of other potential causes of gastrointestinal symptoms in patients with negative breath tests, including undiagnosed celiac disease, sugar malabsorption, and irritable bowel syndrome, using appropriate diagnostic tests. |
| Comparison of Demographic, Clinical, and Laboratory Variables Between Patient Groups | Baseline | Comparison of demographic (age, sex, BMI), clinical (disease duration, symptom severity), and laboratory parameters (e.g., inflammatory markers, pancreatic enzyme markers) between: * patients with SIBO, and * patients with a positive mixed triglyceride breath test indicating impaired pancreatic exocrine function. |
Countries
Italy
Contacts
CONTACTEnrico Celestino Nista
CONTACTSara Sofia De Lucia
PRINCIPAL_INVESTIGATOREnrico Celestino Nista
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Outcome results
None listed